{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:00:54Z","timestamp":1767988854918,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"German Federal Ministry of Health"},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Federal Ministry of Economic Affairs and Energy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The current SARS-CoV-2 pandemic has triggered the development of various SARS-CoV-2 neutralization tests. A wild-type virus (using African green monkey VeroE6 cells), a pseudovirus (using human Caco-2 cells), and a surrogate neutralization test platform were applied to characterize the SARS-CoV-2 neutralization potential of a cohort of 111 convalescent plasma donors over a period of seven months after diagnosis. This allowed an in-depth validation and assay performance analysis of these platforms. More importantly, we found that SARS-CoV-2 neutralization titers were stable or even increased within the observation period, which contradicts earlier studies reporting a rapid waning of Ab titers after three to four months. Moreover, we observed a positive correlation of neutralization titers with increasing age, number of symptoms reported, and the presence of the Rhesus Ag RhD. Validation of the platforms revealed that highest assay performances were obtained with the wild-type virus and the surrogate neutralization platforms. However, our data also suggested that selection of cutoff titers had a strong impact on the evaluation of neutralization potency. When taking strong neutralization potency, as demonstrated by the wild-type virus platform as the gold standard, up to 55% of plasma products had low neutralization titers. However, a significant portion of these products were overrated in their potency when using the surrogate assay with the recommended cutoff titer. In summary, our study demonstrates that SARS-CoV-2 neutralization titers are stable for at least seven months after diagnosis and offers a testing strategy for rapid selection of high-titer convalescent plasma products in a biosafety level 1 environment.<\/jats:p>","DOI":"10.4049\/jimmunol.2100036","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T17:00:35Z","timestamp":1620838835000},"page":"2614-2622","source":"Crossref","is-referenced-by-count":24,"title":["Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19\u2013Convalescent Donors"],"prefix":"10.1093","volume":"206","author":[{"given":"Bernd","family":"Jahrsd\u00f6rfer","sequence":"first","affiliation":[{"name":"Department of Transfusion Medicine, Ulm University , Ulm ,","place":["Germany"]},{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg\u2013Hessen and University Hospital Ulm , Ulm ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0355-7915","authenticated-orcid":false,"given":"R\u00fcdiger","family":"Gro\u00df","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology, Ulm University Medical Center , Ulm ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Seidel","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology, Ulm University Medical Center , Ulm ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8182-9309","authenticated-orcid":false,"given":"Lukas","family":"Wettstein","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology, Ulm University Medical Center , Ulm ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Ulm University , Ulm ,","place":["Germany"]},{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg\u2013Hessen and University Hospital Ulm , Ulm ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6054-4750","authenticated-orcid":false,"given":"Tatjana","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Institute of Virology, Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sixten","family":"K\u00f6rper","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Ulm University , Ulm ,","place":["Germany"]},{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg\u2013Hessen and University Hospital Ulm , Ulm ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Rojewski","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Ulm University , Ulm ,","place":["Germany"]},{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg\u2013Hessen and University Hospital Ulm , Ulm ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin","family":"Lotfi","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Ulm University , Ulm ,","place":["Germany"]},{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg\u2013Hessen and University Hospital Ulm , Ulm ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Weinstock","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Ulm University , Ulm ,","place":["Germany"]},{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg\u2013Hessen and University Hospital Ulm , Ulm ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5777-9225","authenticated-orcid":false,"given":"Erhard","family":"Seifried","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine and Immunohematology, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg\u2013Hessen , Frankfurt ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3605-0136","authenticated-orcid":false,"given":"Victor Max","family":"Corman","sequence":"additional","affiliation":[{"name":"Institute of Virology, Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Drosten","sequence":"additional","affiliation":[{"name":"Institute of Virology, Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7316-7141","authenticated-orcid":false,"given":"Jan","family":"M\u00fcnch","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology, Ulm University Medical Center , Ulm ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Schrezenmeier","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Ulm University , Ulm ,","place":["Germany"]},{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg\u2013Hessen and University Hospital Ulm , Ulm ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"2025030417503657300_r1","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025030417503657300_r2","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025030417503657300_r3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2020","journal-title":"Lancet"},{"key":"2025030417503657300_r4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A randomized trial of convalescent plasma in Covid-19 severe pneumonia","volume":"384","author":"Simonovich","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025030417503657300_r5","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1056\/NEJMoa1405858","article-title":"Transmission of MERS-coronavirus in household contacts","volume":"371","author":"Drosten","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"2025030417503657300_r6","doi-asserted-by":"crossref","first-page":"114031","DOI":"10.1016\/j.jviromet.2020.114031","article-title":"Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma","volume":"288","author":"Christine von Rhein","year":"2020","journal-title":"J. Virol. Methods"},{"key":"2025030417503657300_r7","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/infdis\/jiaa656","article-title":"Independent side-by-side validation and comparison of four serological platforms for SARS-CoV-2 antibody testing","volume":"223","author":"Jahrsd\u00f6rfer","year":"2021","journal-title":"J. Infect. Dis."},{"key":"2025030417503657300_r8","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","article-title":"SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies","volume":"184","author":"Hoffmann","year":"2021","journal-title":"Cell"},{"key":"2025030417503657300_r9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1743-422X-5-138","article-title":"Plaque assay for human coronavirus NL63 using human colon carcinoma cells","volume":"5","author":"Herzog","year":"2008","journal-title":"Virol. J."},{"key":"2025030417503657300_r10","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/s41467-021-21972-0","article-title":"Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection","volume":"12","author":"Wettstein","year":"2021","journal-title":"Nat. Commun."},{"key":"2025030417503657300_r11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"2025030417503657300_r12","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.pathol.2020.09.007","article-title":"Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays","volume":"52","author":"Tan","year":"2020","journal-title":"Pathology"},{"key":"2025030417503657300_r13","doi-asserted-by":"crossref","first-page":"e02438-20","DOI":"10.1128\/JCM.02438-20","article-title":"A new SARS CoV-2 dual purpose serology test: highly accurate infection tracing and neutralizing antibody response detection","volume":"59","author":"Taylor","year":"2021","journal-title":"J. Clin. Microbiol."},{"key":"2025030417503657300_r14","doi-asserted-by":"crossref","first-page":"e1008556","DOI":"10.1371\/journal.ppat.1008556","article-title":"Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2","volume":"16","author":"Breiman","year":"2020","journal-title":"PLoS Pathog."},{"key":"2025030417503657300_r15","doi-asserted-by":"crossref","first-page":"6728","DOI":"10.1172\/JCI141206","article-title":"Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization","volume":"130","author":"Salazar","year":"2020","journal-title":"J. Clin. Invest."},{"key":"2025030417503657300_r16","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood.2020008367","article-title":"Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset","volume":"136","author":"Perreault","year":"2020","journal-title":"Blood"},{"key":"2025030417503657300_r17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41586-020-2912-6","article-title":"Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City","volume":"590","author":"Stadlbauer","year":"2021","journal-title":"Nature"},{"key":"2025030417503657300_r18","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.abd7728","article-title":"Robust neutralizing antibodies to SARS-CoV-2 infection persist for months","volume":"370","author":"Wajnberg","year":"2020","journal-title":"Science"},{"key":"2025030417503657300_r19","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"2025030417503657300_r20","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity","volume":"370","author":"Cantuti-Castelvetri","year":"2020","journal-title":"Science"},{"key":"2025030417503657300_r21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.immuni.2020.06.001","article-title":"Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation","volume":"53","author":"Seydoux","year":"2020","journal-title":"Immunity"},{"key":"2025030417503657300_r22","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00277-020-04169-1","article-title":"Blood type and outcomes in patients with COVID-19","volume":"99","author":"Latz","year":"2020","journal-title":"Ann. Hematol."},{"key":"2025030417503657300_r23","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1111\/bjh.16884","article-title":"COVID-19 and ABO blood group: another viewpoint","volume":"190","author":"G\u00e9rard","year":"2020","journal-title":"Br. J. Haematol."},{"key":"2025030417503657300_r24","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/glycob\/cwn093","article-title":"Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies","volume":"18","author":"Guillon","year":"2008","journal-title":"Glycobiology"},{"key":"2025030417503657300_r25","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/jmv.25757","article-title":"COVID-19 patients\u2019 clinical characteristics, discharge rate, and fatality rate of meta-analysis","volume":"92","author":"Li","year":"2020","journal-title":"J. Med. Virol."},{"key":"2025030417503657300_r26","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMc2005073","article-title":"SARS-CoV-2 Infection in Children","volume":"382","author":"Lu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025030417503657300_r27","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/206\/11\/2614\/61367874\/ji2100036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/206\/11\/2614\/61367874\/ji2100036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T17:59:41Z","timestamp":1741111181000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/206\/11\/2614\/7944634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.2100036","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6]]},"published":{"date-parts":[[2021,6,1]]}}}